196 related articles for article (PubMed ID: 30850724)
1. Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy.
Sakin A; Secmeler S; Arici S; Geredeli C; Yasar N; Demir C; Aksaray F; Cihan S
Sci Rep; 2019 Mar; 9(1):3959. PubMed ID: 30850724
[TBL] [Abstract][Full Text] [Related]
2. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer.
Omar M; Tanriverdi O; Cokmert S; Oktay E; Yersal O; Pilancı KN; Menekse S; Kocar M; Sen CA; Ordu C; Goksel G; Meydan N; Barutca S;
Clin Respir J; 2018 Mar; 12(3):922-929. PubMed ID: 28026133
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer.
Gao L; Zhang H; Zhang B; Zhang L; Wang C
Oncotarget; 2017 Feb; 8(9):15632-15641. PubMed ID: 28152504
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer.
Inagaki N; Kibata K; Tamaki T; Shimizu T; Nomura S
Lung Cancer; 2014 Jan; 83(1):97-101. PubMed ID: 24189108
[TBL] [Abstract][Full Text] [Related]
6. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
[TBL] [Abstract][Full Text] [Related]
7. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).
Eberhardt WE; Gauler TC; Lepechoux C; Stamatis G; Bildat S; Krbek T; Welter S; Grunenwald D; Fischer B; Rodrigo Hde L; Theegarten D; Le Chevalier T; Seeber S; Stuschke M; Poettgen C
Lung Cancer; 2013 Oct; 82(1):83-9. PubMed ID: 23957964
[TBL] [Abstract][Full Text] [Related]
8. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
Langer CJ; Curran WJ; Keller SM; Catalano R; Fowler W; Blankstein K; Litwin S; Bagchi P; Nash S; Comis R
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):469-78. PubMed ID: 8390421
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
Katsui K; Ogata T; Watanabe K; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Acta Med Okayama; 2021 Jun; 75(3):269-277. PubMed ID: 34176930
[TBL] [Abstract][Full Text] [Related]
11. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.
Walraven I; van den Heuvel M; van Diessen J; Schaake E; Uyterlinde W; Aerts J; Koppe F; Codrington H; Kunst P; Dieleman E; van de Vaart P; Verheij M; Belderbos J
Radiother Oncol; 2016 Mar; 118(3):442-6. PubMed ID: 26900091
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Vrankar M; Stanic K
Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
[TBL] [Abstract][Full Text] [Related]
15. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
16. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
17. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.
Sakin A; Sahin S; Atci MM; Sakin A; Yasar N; Geredeli C; Aksaray F; Cihan S
Pulmonology; 2021; 27(1):26-34. PubMed ID: 31839507
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC.
Qin A; Lusk E; Daignault-Newton S; Schneider BJ
Clin Lung Cancer; 2019 Jul; 20(4):e495-e503. PubMed ID: 31088760
[TBL] [Abstract][Full Text] [Related]
19. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
20. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
